FOXL2 Goat Polyclonal Antibody
Goat Polyclonal Antibody against FOXL2
Product Datasheet for 'TA302879'
|Recommend Dilution||ELISA: 1:32,000. WB: 0.3-1ug/ml.IHC:5µg/ml|
|Reactivity||Test: Human, Mouse. Expected from seq similarity: Human, Mouse, Rat, Cow|
|Immunogen||Peptide with sequence C-DSKTGALHSRLDL, from the C Terminus of the protein sequence according to NP_075555.|
|Formulation||Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.|
|Purification||Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. Aliquot and store at -20°C. Minimize freezing and thawing.|
|Gene Name||forkhead box L2|
|Background||Defects in FOXL2 are a cause of blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES) [MIM:110100]; also known as blepharophimosis syndrome. It is an autosomal dominant disorder characterized by eyelid dysplasia, small palpebral fissures, drooping eyelids and a skin fold running inward and upward from the lower lid. In type I BPSE (BPES1) eyelid abnormalities are associated with female infertility. Affected females show an ovarian deficit due to primary amenorrhea or to premature ovarian failure (POF). In type II BPSE (BPES2) affected individuals show only the eyelid defects. There is a mutational hotspot in the region coding for the poly-Ala domain, since 30% of all mutations in the ORF lead to poly-Ala expansions, resulting mainly in BPES type II.|
|Synonyms||BPES; BPES1; PFRK; PINTO; POF3|
|Protein Families||Druggable Genome, Transcription Factors|
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.